A Patient-centric Clinical Trial Design to Comprehensively Evaluate Low-Sodium Oxybate in People with Idiopathic Hypersomnia or Narcolepsy
Abstract Introduction Low-sodium oxybate (LXB; Xywav®) is approved to treat idiopathic hypersomnia in adults and excessive daytime sleepiness or cataplexy in individuals aged ≥ 7 years with narcolepsy. The efficacy and safety of LXB have been demonstrated in randomized controlled trials. This study...
Saved in:
| Main Authors: | Deborah A. Nichols, Teresa L. Steininger, Douglas S. Fuller, M. Todd Kirby, Emily C. Barker, Marisa Whalen, Jessica K. Alexander, Sarah Akerman, David T. Plante |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2025-06-01
|
| Series: | Neurology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s40120-025-00745-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Integrative evidence linking excessive daytime sleepiness, narcolepsy, and hypertension: insights from NHANES, Mendelian randomization, and proteomics
by: Shenghui Feng, et al.
Published: (2025-07-01) -
Objective Sleep–Wake Findings in Patients with Post-COVID-19 Syndrome, Fatigue and Excessive Daytime Sleepiness
by: Livia G. Fregolente, et al.
Published: (2025-03-01) -
Circadian rhythm defects in Prader-Willi syndrome neurons
by: A. Kaitlyn Victor, et al.
Published: (2025-04-01) -
The Clinical and Economic Burden of Idiopathic Hypersomnia and Narcolepsy: A United States Claims-Based Analysis
by: Saad R, et al.
Published: (2025-08-01) -
Evaluation of pitolisant, sodium oxybate, solriamfetol, and modafinil for the management of narcolepsy: a retrospective analysis of the FAERS database
by: Xiaodan Zhou, et al.
Published: (2024-11-01)